Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02644967 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 53 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 |
| clinicaltrials |
| NCT00068172 | Study of PI-88 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 88 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT00130442 | Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | completed | Phase 2 | 134 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 23, 2022 | clinicaltrials |
| NCT00602576 | Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 169 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | completed | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01127451 | Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02626962 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma(GEM1402) | completed | Phase 2 | 52 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT01927419 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma(CheckMate 069) | completed | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 18, 2022 | clinicaltrials |
| NCT01959633 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation(VEMUPLINT) | completed | Phase 1 / Phase 2 | 11 | Fondazione Melanoma OnlusOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04062032 | Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma | completed | Phase 2 | 41 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04066725 | Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma | completed | Phase 2 | 95 | University of UtahOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03278665 | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy(SENSITIZE) | completed | Phase 1 / Phase 2 | 40 | 4SC AGINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02083354 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | completed | Phase 2 | 77 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 1, 2022 | clinicaltrials |
| NCT02225366 | Intratumoral Injections of LL37 for Melanoma | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00910650 | Study of Gene Modified Immune Cells in Patients With Advanced Melanoma(F5) | completed | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT00591734 | RAD001 Plus Bevacizumab in Metastatic Melanoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 27 | University of LouisvilleOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT02320058 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself(CheckMate204) | completed | Phase 2 | 119 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT01335009 | Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma | completed | Phase 2 | 76 | Eisai Inc.INDUSTRY | 4 | Sep 1, 2021 | clinicaltrials |
| NCT00960752 | Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | completed | Phase 2 | 138 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT02071940 | PLX3397 KIT in Acral aNd mucOsal Melanoma(PIANO) | completed | Phase 2 | 7 | The Christie NHS Foundation TrustOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | completed | Phase 1 / Phase 2 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02296112 | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | completed | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT00118274 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 170 | Craig L Slingluff, JrOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT01302496 | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma(TriMix-Ipi) | completed | Phase 2 | 39 | Bart NeynsOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT01321437 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | completed | Phase 2 | 11 | University of California, IrvineOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02493361 | Trial of pIL-12/MK-3475 in Metastatic Melanoma | completed | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma(PREDICT) | completed | Phase 2 | 125 | GlaxoSmithKlineINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03352947 | Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma(INTERIM) | completed | Phase 2 | 79 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Dec 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2022source: clinicaltrials